Jobs

Full-time in Singapore! Director Drug-Resistant Infections Clinical Research Network

COVID-related heads-up: FDA has announced that VRBPAC (Vaccines and Related Biological Products Advisory Committee) will meet on 10 Dec 2020 to discuss the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19. Go here for details.   Dear All, There’s a serious job opportunity in Singapore: The National University of Singapore seeks a full-time Director for

Read More »

More jobs! CARB-X also has openings

Dear All: Building on my recent note about a search for the G20 secretariat lead, we now have CARB-X getting into job creation mode by posting 8 positions across 5 different job openings: Accelerator Lead: coordinates the work of the growing accelerator network for all CARB-X-funded companies. Support Team Lead (three positions): takes responsibility for managing the full range of

Read More »

Research opportunity: Two RFPs from Wellcome Trust in support of the UN IACG

Dear All: I have just learned that Wellcome Trust is seeking applications to address an RFP (Request for Proposal) for two pieces of work designed to support the recently created UN Interagency Coordination Group (IACG) on AMR. RFP #1 is for a review of the roles, responsibilities and remit of UN organisations in relation to AMR, identifying

Read More »

WHO consultancy to support AMR-related messaging / 2 Mar 2020 deadline!

Dear All, WHO has just posted a job opening for a consultant in Geneva to help with spreading the word about AMR by (i) revamping the World Antibiotic Awareness Week (WAAW) campaigns and (ii) facilitating mainstreaming of antimicrobial resistance messages into major global events and scientific conferences. Full details from the posting are below my

Read More »

CARB-X at work! New funding round, new job opportunities

Dear All, Two things on a Friday afternoon: First,CARB-X Funding Round 4 will be open from 12-19 Nov 2019 for Expressions of Interest (EOIs). This round is very focused and seeks only applications for new classes and/or new targets in early development phases (hit-to-lead through Phase 1) targeting a specific list of Gram-negative pathogens (see link,

Read More »
Scroll to Top